Exchange Traded Concepts LLC Raises Stock Position in Vor Biopharma Inc. (NYSE:VOR)

Exchange Traded Concepts LLC boosted its holdings in shares of Vor Biopharma Inc. (NYSE:VOR) by 40.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 165,805 shares of the company’s stock after buying an additional 48,017 shares during the period. Exchange Traded Concepts LLC owned approximately 0.24% of Vor Biopharma worth $116,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Hsbc Holdings PLC raised its stake in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma in the 2nd quarter valued at $53,000. Acadian Asset Management LLC bought a new position in shares of Vor Biopharma during the 1st quarter valued at $126,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vor Biopharma in the 2nd quarter valued at about $63,000. Finally, Renaissance Technologies LLC boosted its holdings in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after acquiring an additional 160,642 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Trading Up 4.8 %

Shares of NYSE VOR opened at $0.71 on Wednesday. The firm has a fifty day simple moving average of $0.83 and a two-hundred day simple moving average of $1.17. The firm has a market capitalization of $48.52 million, a PE ratio of -0.40 and a beta of -0.35. Vor Biopharma Inc. has a 12 month low of $0.63 and a 12 month high of $3.14.

Vor Biopharma (NYSE:VOR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). On average, sell-side analysts predict that Vor Biopharma Inc. will post -1.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on VOR shares. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Barclays decreased their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma currently has an average rating of “Buy” and an average price target of $10.92.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.